Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for JINHAI MED TECH?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from HK$45.1M in FY2016 to HK$46.3M in FY2025 (9-year CAGR +0.3%).
- Net income was negative in FY2018, FY2019, FY2021, FY2023, FY2024, FY2025.
- Operating cash flow was below half of net income in FY2017.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (HKD B) | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 |
| YoY | -2.6% | 1.8% | 104.9% | 10.1% | -7.9% |
| Net Income (HKD B) | -0.00 | 0.00 | -0.00 | -0.02 | -0.02 |
| YoY | -119.5% | — | -771.2% | — | — |
| Operating Cash Flow (HKD B) | 0.02 | 0.02 | -0.01 | -0.02 | -0.03 |
| ROE | -1.0% | 1.9% | -10.2% | -51.9% | -41.1% |
| Gross Margin | 35.3% | 45.4% | 26.4% | 22.8% | 15.5% |
| Net Margin | -1.1% | 2.1% | -6.9% | -35.8% | -36.9% |
| Debt-to-Assets | 28.9% | 38.9% | 39.7% | 44.3% | 41.5% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (HKD B) | 0.05 | 0.04 | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 |
| YoY | — | -1.4% | 6.8% | 9.4% | -56.7% | -2.6% | 1.8% | 104.9% | 10.1% | -7.9% |
| Net Income (HKD B) | 0.01 | 0.00 | -0.00 | -0.00 | 0.00 | -0.00 | 0.00 | -0.00 | -0.02 | -0.02 |
| YoY | — | -65.6% | -255.4% | — | — | -119.5% | — | -771.2% | — | — |
| Operating Cash Flow (HKD B) | 0.04 | -0.01 | -0.01 | 0.04 | 0.04 | 0.02 | 0.02 | -0.01 | -0.02 | -0.03 |
| ROE | 66.4% | 11.6% | -13.0% | -2.8% | 5.1% | -1.0% | 1.9% | -10.2% | -51.9% | -41.1% |
| Gross Margin | 34.4% | 26.4% | 18.7% | 23.9% | 39.4% | 35.3% | 45.4% | 26.4% | 22.8% | 15.5% |
| Net Margin | 14.7% | 5.1% | -7.5% | -1.3% | 5.6% | -1.1% | 2.1% | -6.9% | -35.8% | -36.9% |
| Debt-to-Assets | 62.4% | 23.0% | 26.4% | 43.2% | 35.3% | 28.9% | 38.9% | 39.7% | 44.3% | 41.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Alert
Receivables DaysFinancial Quality
121.3 days, prior FY 35.3 days(+244%)
FY2025 (ended 2025-12-31) · What is this?
- Alert
-
Alert
Net LossesGoing Concern
FY2025 (2025-12-31) HK$-0.02B, FY2024 (2024-12-31) HK$-0.02B
FY2025 (ended 2025-12-31)
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.